JOHN HOPE FRANKLIN CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1838-01-01

Employees: 5K

Market Cap: -

Website: http://www.duke.edu

Clinical Trials

Adherence to Hydroxyurea in Children With Sickle Cell Anemia

Not Applicable

Completed

Conditions: Sickle Cell Anemia

Interventions: Other: standard education
Behavioral: Blood smear education

First Posted Date: 2008-05-06

Last Posted Date: 2013-05-27

Lead Sponsor: Duke University

Target Recruit Count: 31

Registration Number: NCT00672789

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Phase 2

Completed

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: Bevacizumab and Erlotinib

First Posted Date: 2008-05-06

Last Posted Date: 2013-05-13

Lead Sponsor: Duke University

Target Recruit Count: 57

Registration Number: NCT00671970

Locations: 🇺🇸
Duke University Health System, Durham, North Carolina, United States

Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy

Phase 2

Completed

Conditions: Prostate Cancer
Prostatectomy

Interventions: Drug: Sunitinib Malate

First Posted Date: 2008-05-06

Last Posted Date: 2014-08-04

Lead Sponsor: Duke University

Target Recruit Count: 30

Registration Number: NCT00672594

Locations: 🇺🇸
MD Anderson, University of Texas, Houston, Texas, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Not Applicable

Completed

Conditions: Invasive Candidiasis

Interventions: Drug: Preemptive Therapy with Anidulafungin
Drug: Empiric antifungal therapy based on physician discretion.

First Posted Date: 2008-05-06

Last Posted Date: 2015-02-06

Lead Sponsor: Duke University

Target Recruit Count: 64

Registration Number: NCT00672841

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Self System Therapy and Chronic Low Back Pain Trial

Phase 4

Completed

Conditions: Low Back Pain
Depression

Interventions: Behavioral: Self-System Therapy
Behavioral: Education
Other: Standard Care

First Posted Date: 2008-05-06

Last Posted Date: 2023-04-26

Lead Sponsor: Duke University

Target Recruit Count: 137

Registration Number: NCT00672880

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Group Parent Training for Adolescent Eating Disorders

Not Applicable

Completed

Conditions: Adolescent Anorexia Nervosa
Subthreshold Anorexia Nervosa

Interventions: Behavioral: Maudsley Family Therapy
Behavioral: Group Parent Training

First Posted Date: 2008-05-06

Last Posted Date: 2014-09-16

Lead Sponsor: Duke University

Target Recruit Count: 124

Registration Number: NCT00672906

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Cardio Risk of Acute Schizophrenia Olanzapine Duke

Phase 4

Withdrawn

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Olanzapine
Drug: Simvastatin
Drug: Metformin

First Posted Date: 2008-05-06

Last Posted Date: 2014-07-31

Lead Sponsor: Duke University

Registration Number: NCT00672464

Locations: 🇺🇸
John Umstead Hospital, Butner, North Carolina, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)

Phase 1

Terminated

Conditions: Renal Cell Carcinoma

First Posted Date: 2008-05-06

Last Posted Date: 2017-01-12

Lead Sponsor: Duke University

Target Recruit Count: 1

Registration Number: NCT00672178

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: Smoking Abstinence

First Posted Date: 2008-05-06

Last Posted Date: 2014-07-23

Lead Sponsor: Duke University

Target Recruit Count: 62

Registration Number: NCT00672256

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

Phase 1

Withdrawn

Conditions: Melanoma (Skin)

First Posted Date: 2008-04-18

Last Posted Date: 2015-03-13

Lead Sponsor: Duke University

Registration Number: NCT00661336

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy